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Abstract
Background—Relative risks (RR) for cardiovascular disease (CVD) by smoking rate exhibit a 
concave pattern, with RRs in low rate smokers exceeding a linear extrapolation from higher rate 
smokers. However, cigarettes/day does not by itself fully characterize smoking-related risks. A 
reexamination of the concave pattern using a comprehensive representation of smoking may 
enhance insights.
Material—Data were from the Atherosclerosis Risk in Communities (ARIC) Study, a prospective 
cohort enrolled in four areas of the U.S. in 1987–89. Follow-up was through 2008. Analyses 
included 14,233 participants, 245,915 person-years and 3,411 CVD events.
Results—The concave RRs with cigarettes/day were consistent with cigarettes/day modifying a 
linear RR association of pack-years with CVD, i.e., strength of the pack-years association 
depended on cigarettes/day, indicating that the manner of pack-years accrual impacted risk. 
Smoking fewer cigarettes/day for longer duration was more deleterious than smoking more 
cigarettes/day for shorter duration (P<0.01). For 50 pack-years (365,000 cigarettes), estimated 
RRs of CVD were 2.1 for accrual at 20 cigarettes/day and 1.6 for accrual at 50 cigarettes/day. 
Correspondence to: JH Lubin lubinj@mail.nih.gov. 
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Years since smoking cessation did not alter the diminishing strength of association with increasing 
cigarettes/day. Analyses that accounted for competing risks did not affect findings.
Conclusion—Pack-years remained the primary determinant of smoking-related CVD risk; 
however, accrual influenced RRs. For equal pack-years, smoking fewer cigarettes/day for longer 
duration was more deleterious than smoking more cigarettes/day for shorter duration. This 
observation provides clues to better understanding the biological mechanisms, and reinforces the 
importance of cessation rather than smoking less to reduce CVD risk.
Introduction
Although cigarette smoking prevalence has declined in most Western countries, it remains 
high in many countries and consequently smoking remains an important risk factor for 
cardiovascular disease (CVD) (WHO Report On The Global Tobacco Epidemic, 2013; 
available at http://www.who.int/tobacco/global_report/2013/en/). Investigators have 
consistently reported that relative risks (RR) for CVD by cigarettes/day exhibit a concave 
pattern, implying that the RR per cigarette/day decreases with greater cigarettes/day 1–3. 
Several reviews have discussed possible mechanisms that link smoking to CVD, including 
the non-linear effects 2–9; however, the precise smoking rate-dependent biologic 
mechanisms responsible for the concave pattern remain uncertain.
Cigarettes/day represents a metric of exposure rate (the time weighted average over the 
period of active consumption), and thus is not a quantitative measure of cigarette smoke 
exposure. Furthermore, it is well recognized that analyses based on cigarettes/day alone, or 
indeed smoking duration alone or pack-years alone, provide an incomplete characterization 
of smoking-related disease risk. Consequently, a comprehensive description of risks by 
smoking requires a more complete representation of exposure. Starting with cigarettes/day, 
duration, and/or pack-years, investigators often adjust one metric for another or cross-
tabulate RRs for two factors with never-smokers as the referent group. Less frequently, 
investigators use a single comprehensive smoking index that simultaneously incorporates 
multiple smoking-related components 10,11. The typical approach computes the joint RRs 
with cigarettes/day and smoking duration, although this choice leads to problems of 
interpretation12–14. For example, in a simple log-linear RR model with cigarettes/day and 
duration, the cigarettes/day parameter represents the ln(RR) per cigarette/day with duration 
held fixed. Because duration is fixed, RRs for increasing cigarettes/day necessarily embed 
increasing total pack-years. For example, for 30 years of smoking, a comparison of RRs at 
20 and 30 cigarettes/day reflects not only different smoking rates but also different total 
exposures, i.e., 30 and 45 pack-years, respectively, or nearly 110,000 (≈15×20×365.25) 
additional cigarettes. Similarly, at fixed cigarettes/day, RRs at two different durations of 
smoking include effects of increasing pack-years. Hence, the cigarettes/day and duration 
parameters are not interpretable as distinct, unrelated effects.
We analyze RRs for pack-years and cigarettes/day, which allows a more direct interpretation 
of parameters, in which smoking rate serves to modify RR trends with pack-years. In this 
approach, cigarettes/day represents the relative influence of exposure accrual on the RR for a 
given pack-years, i.e., the differential in the RRs at a fixed pack-years when delivered at 
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lower smoking rates for longer durations or higher rates for shorter durations. This approach 
reinterprets the non-linear RRs for cigarettes/day as a “smoking rate effectiveness factor” or 
“delivery rate effect”. For example, for individuals who smoked 20 cigarettes/day for 50 
years or 30 cigarettes/day for 33.3 years or 50 cigarettes/day for 20 years, the analysis below 
estimates RRs of 2.2, 1.9 and 1.7, respectively, even though exposure for all individuals was 
50 pack-years (365,000 cigarettes).
Our analysis considers two issues: (i) the joint RRs by pack-years and cigarettes/day for 
CVD, coronary heart disease (CHD) and stroke; and (ii) the modification of smoking-related 
RRs for CVD by smoking-related behaviors, age started smoking, extent of inhalation, years 
since cessation and additional use of cigars and pipes.
Material and Methods
Study design
The Atherosclerosis Risk in Communities Study (ARIC) is a large prospective cohort study 
conducted in four areas of the U.S.: Forsyth County, NC; Jackson, MS; Washington County, 
MD; the northwest suburbs of Minneapolis, MN. Enrollment occurred between 1987 and 
1989 using a probability-based sample of adults aged 45–64 years. Study details have been 
provided previously 15–18. Study personnel collected a wide variety of data from clinical 
examinations and from personal interviews at baseline enrollment and at three clinic visits: 
1990–1992 (visit 2), 1993–1995 (visit 3) and 1996–1998 (visit 4). Annual telephone calls 
collected information from participants or their surrogates on vital status, hospital visits and 
other factors.
For this analyses, we followed those participants without a pre-enrollment history of 
coronary heart disease or stroke through the earliest date of CVD incidence, loss to follow-
up, death or 31 December 200818. We ascertained outcome information on CVD through 
annual telephone interviews and surveillance of hospital discharge records in the study areas 
and death certificates. Events were validated by examination of hospital records, death 
certificates and, when available, autopsy records, with outcomes classified according to 
ARIC Study criteria 18. CVD encompassed CHD and stroke. CHD included a validated, 
definite or probable hospitalized myocardial infarction, a definite CHD death, an 
unrecognized myocardial infarction defined by electrocardiographic reading or coronary 
revascularization 17. A stroke event comprised a validated, definite or probable hospitalized 
ischemic or hemorrhagic stroke.
Questionnaires administered at baseline and subsequent clinic visits provided information on 
smoking status and cigarettes/day, while the annual telephone contacts provided additional 
information on smoking status. For cigarettes/day, we used baseline information only. This 
choice likely had minimal effect, since few individuals modified their cigarettes/day. At 
baseline, there were 42% never-smokers, 32% former smokers and 26% current smokers, 
half of whom stopped smoking by the end of 2008. Among current and former smokers at 
baseline who had follow-up smoking information from one or more clinic visits, only 15% 
and 8%, respectively, changed their smoking status. In addition, for continuing smokers, the 
mean cigarettes/day during follow-up was on average within 1–4 cigarettes/day of their 
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baseline value. Additionally, smoking-years from baseline through visit 4 represented a 
relatively limited percentage of the lifetime years of consumption. Thus, cigarettes/day at 
baseline provided a good estimate of the time weighted average cigarettes/day throughout 
follow-up. The clinic questionnaires and the yearly telephone contacts yielded time-
dependent information on smoking status, which enabled time-dependent calculation for 
duration of smoking, pack-years and time since smoking cessation. For the analyses, we 
defined former smokers as those who last smoked one or more years prior.
Study personnel obtained three blood pressure (BP) measurements using a random-zero 
sphygmomanometer with the participant seated, with BP determined as the mean of the last 
two values. We defined hypertension as systolic blood pressure ≥140mmHg, diastolic blood 
pressure ≥90mmHg or current use of antihypertensive medication. We conducted a fasting 
blood collection and measured glucose and plasma total cholesterol by standard enzymatic 
methods. We designated diabetes at baseline as a self-reported history of, or treatment for, 
diabetes, a fasting glucose level of 126 mg/dL or greater, or a casual blood glucose level of 
200 mg/dL or greater 18.
The initial dataset included 14,878 subjects and 3,603 CVD events. We excluded 751 
participants with missing data, including 212 CVD events, leaving 14,127 participants with 
3,391 CVD events and 232,002 person-years of follow-up. Exclusions resulted from missing 
information for smoking (247 subjects and 59 CVD cases), lipid measurements (228 
subjects and 64 cases), body mass index (BMI) and diagnosed diabetes mellitus (43 subjects 
and 15 cases), alcohol use (78 subjects and 24 cases) and other variables (155 subjects and 
50 cases). There were 2,321 non-CVD deaths during follow-up, with 1,241 cancers 
(including 352 lung, 97 breast, 80 pancreas, 80 colon and 65 prostate cancer deaths), 468 
diseases of the circulatory system (including 72 atherosclerosis, 34 hypertensive disease, 27 
congestive heart failure and 23 aortic aneurisms), 236 respiratory diseases (including 140 
chronic obstructive pulmonary disease deaths) and 376 other causes. In addition, there were 
297 (2%) participants with missing or unknown status which were censored at last contact.
Data structure
We used Poisson regression to estimate relative risks (RR), with data summarized in a 
multidimensional person-years table. The cross-classification variables included attained age 
(<54, 54–55, …, 78–79, ≥80), calendar period (<1990, 1990–94, 1995–1999, 2000–2004, 
2005–2009), birth year (<1930, 1930–34, 1935–39, ≥1940), study site, sex, race (White, 
African-America, Asian-American, Other), BMI (<25.0, 25.0–29.9, 30.0–34.9, ≥50 kg/m2), 
alcohol intake in gm-ethanol/week (<40, 40–107, ≥108), diagnosed high BP, diagnosed 
diabetes mellitus, total cholesterol (<5.2, 5.2–6.1, ≥6.2 mmol/L), ever use of cigars/pipes, 
education (<12 years, high school/vocational school and college, graduate or professional 
school), cigarettes smoked per day (0, 1–4, 5–9, …, 45–49, ≥50), pack-years (0, 1–9, 10–19, 
20–24, …, 55–59, ≥60), years since last smoked (<1, 1–4, 5–9, 10–19, ≥20), age first 
smoked (<16, 16–17, 18–19, ≥20) and inhalation (never/seldom, moderately, deeply). We 
used fine categorizations for the primary analytic variables (age, calendar year, cigarettes/
day, pack-year, etc.). For other variables, we selected broader categories that both covered 
the full range of values and allowed for sufficient numbers of CVD cases. For each cell, we 
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accrued person-time, counted disease events and computed person-years weighted means for 
continuous variables.
Competing risks could influence results since those who accrued longer follow-up or were 
lighter smokers may be more likely to incur CVD events, while heavier smokers were more 
likely to be selectively removed from follow-up due to other diseases, in particular lung 
cancer. We therefore conducted analyses using competing risks methodology that 
incorporated multiple outcomes, including incident CVD, lung cancer, other selected 
smoking-related cancers (esophagus, larynx, oropharynx, bladder, kidney, stomach, colon, 
rectum and pancreas) and mortality from all other causes 19,20. For these analyses, we had to 
restrict follow-up, since detailed cancer incidence data were available only through 31 
December 2006. Consequently, we first compared results for the full follow-up with results 
for the restricted follow-up, which then served as a basis for comparison of results under 
competing risks methods.
Relative risk models
We modeled disease rate as r(s, z) = exp(αz) × RR(s), where z and α were vectors of 
adjustment variables and parameters, respectively. For categories of cigarettes/day, smoking 
duration or pack-years, denoted s, we modeled RR(s) using indicator variables and the 
standard exponential form. We computed joint RRs for the cross-tabulation of pack-years 
and cigarettes/day, relative to never-smokers, and observed that RR trends with pack-years 
were approximately linear within each category of cigarettes/day. Since a linear slope fully 
described the pack-years-related RRs within cigarettes/day categories, the goal was to 
characterize the linear trends and their variations with cigarettes/day.
Our models were based on continuous pack-years, denoted d,. We started with a linear 
model,
(1)
where β was the slope parameter, i.e., the excess RR/pack-year. However, since linearity 
occurred only within cigarettes/day categories, we extended equation 1 for S categories of 
cigarettes/day, s=1,…,S:
(2)
where ds equaled d within category s and zero otherwise and β1, …, βS were slope 
parameters.
The slope measured the strength of CVD and pack-years association relative to never-
smokers within each cigarette/day category, while variations among the slope parameters 
(β’s) reflected the influence of smoking rate on the strength of association. We modeled 
variations of the slope with continuous cigarettes/day (n) using:
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(3)
where β g(n) defined the linear slope at n cigarettes/day. We explored various forms for 
ln[g(.)] including restricted cubic splines and various parametric forms using n, n2, ln(n) and 
ln(n)2. The simple power function g(n) = exp{γ ln(n)} = nγ, with g(0) = 0, fitted the data 
well and resulted in the minimum Akaike Information Criterion 21, suggesting it was the 
preferred form. None of various parametric extensions, including g(n) = exp{γ1 ln(n) + γ2 
n}, significantly improved fit.
We evaluated the interactions of several potential smoking-related effect modifiers by 
extending equation (3) for categories of a factor, e.g., years since smoking cessation. For 
categorical factor x with levels f = 1,…, F, we fitted
(4)
where βfdgf(n) replaced β d g(n). The difference in the deviances of models 3 and 4 
provided a likelihood ratio test of no effect modification.
Adjustment variables (z) included study site (4 levels), sex, birth cohort (year of birth 
categories <1930, 1930–34, 1935–39, 1940–1945), race, BMI, years of schooling, gm-
ethanol/week alcohol consumption (never and tertiles based on cases), high BP, diabetes 
mellitus and total cholesterol. We adjusted for attained age by including four continuous 
variables, age and its natural logarithm for males and for females. We included an indicator 
variable for never smokers who used cigars or pipes. For cigarette smokers, we did not 
define a cigarette-equivalence for cigar and pipe use due to data limitations and the potential 
for increased misclassification, but rather evaluated cigar or pipe use as an effect modifier.
Analyses used the Epicure software package 22.
The institutional review board of each participating university and the Office of Human 
Subjects Research Protections of the National Institutes of Health approved the study 
protocol, and all participants provided informed consent. All authors have no declared 
conflicts of interest.
Results
Marginal and adjusted relative risks for cigarette smoking variables
RRs with each smoking-related metric—cigarettes/day, duration of cigarette smoking, and 
pack-years—increased then leveled at higher categories (Table 1). However, a single 
smoking variable did not fully characterize risk, as model fit improved with inclusion of a 
second smoking variable (P<0.01). After adjustment for cigarettes/day or for duration, RRs 
by pack-years (representing 1–9 cigarettes/day or ≥50 years duration, footnoted columns c 
and d, respectively) continued to exhibit an increasing trend. After adjustment for pack-
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years, RRs decreased with cigarettes/day and, correspondingly, increased with duration of 
smoking, indicating a stronger pack-years association at lower cigarettes/day and longer 
durations.
Joint relative risks for pack-years and cigarettes/day
RRs increased with pack-years, but departed from linearity (P<0.01) (Figure 1, upper left 
panel, dash line). For the joint RRs, relative to never-smokers, RRs by pack-years increased 
within each cigarettes/day category (Figure 1 and eAppendix, eTable 1). Trends were 
consistent with linearity within each category, except the 10–19 cigarettes/day category 
(P=0.01), where the difference between never-smokers and the lowest pack-years category 
induced non-linearity (dot line, among smokers P=0.25 for the test of non-linearity). The 
figure highlights the variation in the slopes. The excess RR/pack-year estimates for the five 
cigarettes/day categories were 0.046, 0.031 (0.065 after adjustment for never/ever smoker), 
0.024, 0.017 and 0.011, respectively, revealing a declining strength of association with 
increasing cigarettes/day (P<0.01 for the test of γ=0 in equation 3).
The plot of the slope estimates by mean cigarettes/day revealed a deceasing strength of 
association across the full range of cigarettes/day and were well-described by equation 3 
(Figure 2). For <10 cigarettes/day smokers, there was substantial uncertainty in the excess 
RR/pack-year estimate, due to a limited range for pack-years (the 25th to 75th percentile 
interval was 2.6 to 9.6 pack-years). Splitting the category into 1–4 and 5–9 cigarettes/day 
resulted in excess RR/pack-year estimates of 0.097 and 0.038, respectively, indicting a 
continued strengthening of the association at lower smoking rates (Figure 2, open symbol). 
The non-linear excess RR/pack-year pattern with cigarettes/day represented an “inverse 
smoking rate effect”, suggesting that for equal pack-years, smoking fewer cigarettes/day for 
longer duration was more deleterious than smoking more cigarettes/day for shorter duration.
Smoking risks for coronary heart disease and stroke
There were 2,705 CHD and 1,011 stoke events. As in Table 1, RRs by pack-years (Figure 3, 
upper panels) and by cigarettes/day increased for CHD and for stroke (Table 2). The RRs by 
cigarettes/day appeared slightly larger for CHD, but homogeneity of the RRs by type of 
outcome was not rejected (P=0.15). With adjustment for cigarettes/day, RRs by pack-years 
increased for both outcomes. The inverse smoking rate pattern occurred for both CHD and 
stroke, although stroke appeared to exhibit a greater rate of decline. The plotted estimates of 
excess RR/pack-year by mean cigarettes/day and the fitted equation 3 (Figure 3, lower 
panels) revealed homogeneity of the inverse smoking rate effect by outcome (P=0.57).
Effect modification by smoking-related factors
For age started smoking, depth of inhalation, and additional use of cigars/pipes, the 
estimated RR by pack-years increased within each category of these variables (Table 3). The 
RR trends with pack-years were roughly similar within each level. As in Figure 2, the excess 
RR/pack-year estimates declined smoothly with cigarettes/day within each level of age 
started smoking, inhalation and use of cigars/pipes (aAppendix eFigures 1–3, with eTable 2 
providing parameter estimates). The fitted excess RR/pack-year estimates at 20 
cigarettes/day from equation 4 were similar across levels, and hypothesis tests did not reject 
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homogeneous by age started smoking (P=0.50), method of inhalation (P=0.74) or additional 
use of cigars/pipes (P=0.79) (Table 3).
In contrast, RR trends with pack-years significantly diminished with years since cessation of 
smoking (P<0.01) (Figure 4, left panels). The fitted excess RR/pack-year estimates at 20 
cigarettes/day declined with cessation starting five years and more after cessation (P<0.01) 
(Table 3). Although pack-years-related risks declined with cessation, the inverse smoking 
rate patterns for each cessation category were similar (Figure 4, right panels).
Smoking and CVD under a competing risks model
For the competing risks analysis, follow-up time accrued through 2006. We omitted 803 
participants with a pre-enrollment diagnosis of cancer, leaving 13,324 participants, with 
200,347 person-years and 4,945 total events, including 2,638 CVD cases, 350 lung cancers, 
684 other smoking-related cancers (including 112 bladder, 280 colon and rectum and 114 
stomach cancers) and 1,273 deaths from other causes (including 401 other cancers, 363 
diseases of the circulatory system and 147 diseases of the respiratory system). The 
eAppendix presents detailed results. Competing risks adjustment had minimal impact on 
results. The decreasing smoking rate patterns, i.e., estimates of γ in equation 3, with 95% CI 
were −0.70 (−0.87, −0.52) for the full data analysis in Figure 3, −0.71 (−0.90, −0.53) for the 
restricted follow-up through 2006 and −0.75 (−0.96, −0.55) in the competing risks analysis, 
while the estimated RRs for 50 pack-years accrued at a rate of 20 cigarettes/day were 2.1 
(2.0, 2.4), 2.2 (1.2, 2.5) and 2.1 (1.9, 2.4), respectively.
Discussion
In our data, RRs for CVD increased for each smoking metric: cigarettes/day, smoking 
duration, and pack-years. In addition, there was a concave pattern for the RRs by cigarettes/
day, indicating that the RR per cigarette/day decreased with greater cigarettes/day 1–3. 
However, any interpretation must acknowledge that cigarettes/day represents an exposure 
rate metric and not a quantitative measure of exposure to cigarette smoke, and that no single 
metric, cigarettes/day, smoking duration, or pack-years, fully characterizes smoking-related 
risks. Using joint RRs for pack-years and cigarettes/day, the concave RR pattern with 
cigarettes/day was consistent with cigarettes/day modifying a linear RR association for CVD 
and pack-years, i.e., the strength of association declined with smoking rate. Our analyses 
reaffirmed pack-years as the preeminent smoking-related risk factor for CVD, but also 
demonstrated that the manner of accrual of pack-years influenced CVD risk levels. There 
was an inverse smoking rate pattern, whereby smoking fewer cigarettes/day for longer 
duration was more deleterious than smoking more cigarettes/day for shorter duration. For 50 
pack-years (365,000 cigarettes), the estimated RR of CVD was 2.1 if exposure accrued at 20 
cigarettes/day and 1.6 if exposure accrued at 50 cigarettes/day. This inverse rate pattern was 
quantitatively comparable for CHD and stroke.
The observed inverse rate pattern may be due to smoking rate-dependent pathophysiologic 
mechanisms of CVD risks. Several reviews have described possible mechanisms for 
smoking-related CVD, and in particular the non-linear RRs for cigarettes/day 1–3,5–9. 
Factors that link cigarette smoking to CVD which may contribute to the non-linear 
Lubin et al. Page 8
Epidemiology. Author manuscript; available in PMC 2017 June 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
cigarette/day association include nicotine stimulation with enhanced oxygen demand and 
vasoconstriction, carbon monoxide (CO) induced hemodynamic effects, increased 
inflammation arising from reduced anti-oxidant compounds, particulates and other 
constituents of tobacco smoke, insulin sensitivity, and alterations in lipid profiles 4,8,9. For 
example, CO, a combustion product of cigarette smoke, has an affinity for hemoglobin and 
exhibits smoking rate-dependent effects. Among current smokers, the ratio of serum 
carboxyhemoglobin (COHb) to cigarettes/day decreased with greater smoking intensity 23. 
Polycyclic aromatic hydrocarbons (PAHs), including benzo[a]pyrene, result from 
incomplete combustion of tobacco and other organic products, and are associated with 
increased CVD risk 9. PAH exposure can activate the aryl hydrocarbon receptor (AhR) 
pathway and thereby induce a vascular inflammatory response, including the progression of 
atherosclerosis 9,24–26. Investigators reported that DNA adduct levels per unit PAH exposure 
were higher in environmentally exposed individuals than in workers exposed at occupational 
levels 27,28.
Cigarette smoking may also influence risk through intensity-dependent variations in its 
impact on non-tobacco CVD risk factors, although evidence for this is circumstantial. Law 
and Wald suggested that inflammation-induced platelet aggregation dominates at low 
smoking intensities while other mechanisms—e.g., increased fibrinogen, reduced high-
density lipoprotein cholesterol (HDL), and increased COHb—dominate at higher 
intensities 3.
Exposure bias may also have contributed to the inverse smoking rate pattern, whereby heavy 
smokers inhaled less vigorously following nicotine satiation, resulting in “reduced potency”, 
with the reported cigarettes/day increasingly overestimating internal exposure. Using 
cotinine as a biomarker of smoking rate, studies have reported that cotinine levels increased 
approximately linearly through about 15–20 cigarettes/day 23,29–38. However, trends at 
higher smoking rates have been complex. In some studies, cotinine concentrations increased 
with cigarettes/day, then leveled and even declined 29,30,32,37. Other studies have reported 
trends that continued to increase without substantial diminution 30,33,35,36,39,40 or with only 
modest diminution 23,29–31,34,37. In our data, the inverse smoking rate pattern occurred 
across the full range of cigarettes/day, and consequently was incompatible with any 
presumed inhalation bias. A sensitivity analysis in conjunction with a smoking and lung 
cancer study used urinary cotinine to adjust cigarettes/day and found that the cotinine-
adjusted estimates of excess RR/pack-year within smoking rate categories indeed increased, 
since reported cigarettes/day reflected an overestimate. Nonetheless, the shape of the inverse 
smoking rate effect was unaffected, since the cotinine-adjusted cigarettes/day at higher rates 
correspondingly represented lower adjusted rates 41, again suggesting inhalation bias did not 
greatly influence our results.
Competing risks may have impacted our observed inverse cigarettes/day effects, whereby 
those who accrued longer follow-up or were lighter smokers may have been more likely to 
have incurred CVD events, while heavier smokers were selectively removed from follow-up 
due to other diseases, in particular lung cancer. We conducted competing risks analyses that 
incorporated incident CVD, lung cancer, other selected smoking-related cancers and 
mortality from all other causes 19,20. However, we found that consideration of competing 
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risks had no appreciable effect on the results which suggested that any potential bias from 
competing risk considerations was minimal. This absence of impact was likely due to the 
relatively small numbers of cancer events, particularly lung cancer, compared to CVD events 
and to the relatively small number of current smokers (27.4% at enrollment), who had the 
highest smoking-related risk.
Our results must be interpreted with caution. This analysis is the first to evaluate the effects 
of exposure accrual, comparing the relative impact on the strength of the association of 
pack-years and CVD for smoking fewer cigarettes/day for longer duration with more 
cigarettes/day for shorter duration. At low smoking rates, there was substantial uncertainty 
due to the limited range of pack-years, and additional analyses are needed to determine 
whether the inverse smoking rate pattern continues for even lower rate smokers, as in our 
data, or flattens or decreases. Our analyses did not additionally adjust for exposure to 
environmental tobacco smoke, either in never-smokers or in smokers, and this may have 
underestimated smoking risks. In our data, the RR in never-smokers for exposure to any 
environmental tobacco smoke was of modest magnitude (RR=1.1 with 95% CI 1.0 to 1.3), 
and additional adjustment for any environmental tobacco smoke exposure had minimal 
impact on the smoking rate patterns.
Finally, inference for the inverse smoking rate effect arose from the characterization of pack-
year trends within categories of cigarettes/day. A comparable analysis could have evolved 
from the joint RRs of pack-years and duration of smoking, and indeed the RR trends for 
pack-years increased in strength with increasing duration of smoking. However, this 
approach was more complex because trends in RRs with pack-years within categories of 
duration deviated from simple linear relationships and therefore there was no set of linear 
slope estimates that fully characterize smoking-related RRs.
In summary, the ARIC data confirmed the deleterious consequences of cigarette smoking on 
CVD risk. While pack-years represented the principal determinant of smoking-related CVD 
risk, results demonstrated that the manner of exposure accrual had consequences for 
smoking-related risks. Across the full range of cigarettes/day, smoking fewer cigarettes/day 
for longer durations was more deleterious than smoking more cigarettes/day for shorter 
durations. The precise reasons for this inverse smoking intensity pattern remain uncertain.
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Figure 1. 
Relative risks of cardiovascular disease for categories of pack-years of cigarette smoking 
(solid symbol) relative to never-smokers for all data and within categories of cigarettes/day 
(CPD) and fitted models, including: linear (solid line), linear-exponential (dash line) and 
linear adjusted for ever-smoked cigarettes (dot line). All results adjusted for age, birth year, 
sex and other factors (see text).
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Figure 2. 
Estimated excess relative risk/pack-year (ERR/PKY) for cardiovascular disease within 
categories of cigarettes/day (solid symbol), with the lowest category further divided into 1–4 
and 5–9 cigarettes/day (open symbol), and fitted models for continuous pack-years and 
cigarettes/day. All results adjusted for age, birth year, sex and other factors (see text).
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Figure 3. 
For coronary heart disease (left panels) and stroke (right panels), relative risks for categories 
of pack-years of cigarette smoking (solid symbol) relative to never-smokers with fitted linear 
(solid line) and linear-exponential (dash line) model (upper panels) and estimated excess 
relative risk/pack-year within categories of cigarettes/day (solid symbol) and fitted models 
for continuous pack-years and cigarettes/day (solid line) (lower panels). All results adjusted 
for age, birth year, sex and other factors (see text).
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Figure 4. 
For years since cessation of smoking, relative risks for cardiovascular disease by categories 
of pack-years of cigarette smoking (solid symbol) relative to never-smokers with fitted linear 
(solid line) and linear-exponential (dash line) models (left panels) and estimated excess 
relative risk/pack-year within categories of cigarettes/day (solid symbol) and fitted models 
for continuous pack-years and cigarettes/day (solid line) (right panels). All results adjusted 
for age, birth year, sex and other factors (see text).
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